NIH Clinical Center Search the Studies: Study Number, Study Title

Protocol Details

A Pilot Clinical Trial of Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma

This study is NOT currently recruiting participants.

Summary | Eligibility | Citations | Contacts




Sponsoring Institute

National Cancer Institute (NCI)

Recruitment Detail

Type: Completed Study; data analyses ongoing
Gender: Male & Female
Min Age: 18 Years
Max Age: N/A

Referral Letter Required


Population Exclusion(s)

Pregnant Women;


Bladder Cancer;
Molecular Profiles

Recruitment Keyword(s)



Urothelial Carcinoma;
Bladder Cancer;
Urinary Bladder Neoplasms

Investigational Drug(s)


Investigational Device(s)



Drug: 75 approved agents
Other: COXEN

Supporting Site

National Cancer Institute


Advanced urothelial cancer has no cure. But only a few chemotherapy drugs have been tested for it. The Co-eXpression ExtrapolatioN (COXEN) model predicts if cells respond to treatment. It may also help determine which drugs fight urothelial cancer based on the characteristics of a tumor. Researchers want to test if this model can choose the best therapy for advanced urothelial cancer within 3 weeks and how tumors respond to the next best therapy.


To test if the COXEN model can choose the best therapy for advanced urothelial cancer within 3 weeks.


People ages 18 and older whose urothelial cancer has spread after at least 1 line of chemotherapy


Participants will be screened with medical history, physical exam, blood and urine tests, and tumor scans.

Participants will provide a tumor sample from a previous surgery and a new biopsy. A needle will remove a small piece of tumor.

Participants will repeat screening tests, plus have an EKG and scan. For the scan, they will get an injection of radioactive drug. They will lie in a machine that takes pictures.

Participants will take the drugs assigned by the COXEN model. They will have visits every 2 3 weeks. These will include blood and urine tests.

Participants will have tumor scans every 8 9 weeks.

Participants may have another biopsy.

Participants will take the drugs until they can t tolerate the side effects or their cancer worsens. They may be assigned to a second COXEN therapy.

Participants will have a follow-up visit 4 5 weeks after their last drug dose.

Participants will be contacted by phone every few months until death.

--Back to Top--



-Patients must have a histologically confirmed diagnosis of metastatic, progressive urothelial carcinoma of the bladder, urethra, ureter, or renal pelvis.

-Patients must have progressive metastatic disease defined as new or progressive lesions on cross-sectional imaging.

-Patients must have at least:

--One measurable site of disease (according to RECIST criteria), defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as more than or equal to 20 mm with conventional techniques or as less than or equal to 10 mm with spiral CT scan.

--Or, appearance of one new bone lesion

-Patients must have been previously treated with at least one prior cytotoxic chemotherapy regimen or agent. Patients may have received any number of prior cytotoxic agents.

-Archival tumor tissue must be available for enrollment.

-Tumor amenable to biopsy will be mandatory for this study.

-Age more than or equal to 18 years. ECOG performance status less than or equal to 2 (Karnofsky more than or equal to 60%,).

-Patients must have normal organ and marrow function as defined below:

--hemoglobin more than or equal to 9 g/dL

--leukocytes more than or equal to 3,000/mcL

--absolute neutrophil count more than or equal to 1,200/mcL

--platelets more than or equal to 75,000/mcL

--total bilirubin within normal institutional limits

--AST(SGOT)/ALT(SGPT) less than or equal to 2.5 X institutional upper limit of normal

--creatinine 1.5 x the normal institutional limits


--creatinine clearance more than or equal to 40 mL/min/1.73 m2

-Because many of the therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.

-HIV-positive patients on combination antiretroviral therapy may be eligible if there are no pharmacokinetic interactions with the agents used on the study, stable on CART therapy and CD4 is >200 and viral load is undetectable.

-Ability of subject to understand and the willingness to sign a written informed consent document.


-The patient has received cytotoxic chemotherapy (including investigational cytotoxic chemotherapy) within 3 weeks or biologic agents (e.g., cytokines or antibodies) within 4 weeks prior to study enrolllment.

-Patients who are receiving any investigational agents.

-Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events. Patients with brain metastases that are stable after more than or equal to 1 year after primary surgery or radiation will not be excluded.

-The subject has not recovered to baseline or CTCAE less than or equalto Grade 1 from toxicity due to all prior therapies except alopecia and other non-clinically significant AEs.

-Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

-Patients who are Hepatitis B or C positive.

-Pregnant women are excluded from this study because the agents used in the study have the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with these agents, breastfeeding should be discontinued if the mother is treated with these agents. These potential risks may also apply to other agents used in this study.

--Back to Top--


Not Provided

--Back to Top--


Principal Investigator

Referral Contact

For more information:

Andrea B. Apolo, M.D.
National Cancer Institute (NCI)
(301) 480-0536

Lisa Ley, R.N.
National Cancer Institute (NCI)
BG 10 RM 13N254
(240) 858-3524

NCI Referral Office
National Institute of Health Clinical Center (CC), 9000 Rockville Pike, Bethesda, Maryland 20892, United States: NCI Clinical Trials Referral Office

Clinical Trials Number:


--Back to Top--